Closing a Series A round isn't just about the announcement. It's about sleepless nights, countless pitch decks, and the unwavering belief that your mission matters enough to change lives. Today, I want to pull back the curtain on Luna Health's journey to securing Series A funding and share what this milestone really means for the millions of people living with diabetes.
When we started Luna Health, we were haunted by a statistic that most people don't know: over 80% of the glucose improvement from automated insulin delivery happens while people sleep. Yet millions of people with Type 1 and Type 2 diabetes who rely on insulin pens have no access to this life-changing technology.
Picture this: someone with diabetes goes to bed with perfect glucose levels, only to wake up feeling terrible because their blood sugar spiked or dropped during the night. This happens every single night for millions of people worldwide. Traditional insulin pumps exist, but they're complex, expensive, and require a complete lifestyle change that many people aren't ready for.
We knew there had to be a better way. What if we could capture that critical and potentially life-changing glucose improvement at night without asking people to change their diabetes management completely? What if automated insulin delivery could work alongside insulin pens, rather than replacing them?
That question became our obsession.
Creating the world's smallest iCGM-compatible insulin patch pump wasn't just an engineering challenge—it was a mission to democratize automated insulin delivery. Our team spent countless hours in labs, talking to people with diabetes, and refining our closed-loop algorithm. Since you can't remove basal/long-acting insulin once you take it, it's a super complex problem to automate.
The breakthrough came when we realized we didn't need to solve everything at once. By focusing on nighttime glucose control—where automation has the greatest impact—we could dramatically reduce complexity and costs while still delivering life-changing results.
Luna works differently from anything else made thus far for diabetes; it is a new type of therapy. During the day, people continue using their insulin pens as usual. But when they sleep, our tiny patch pump takes over, delivering automated doses of rapid-acting insulin based on continuous glucose monitoring data. No lifestyle disruption, no steep learning curve, just better glucose control where it matters most.
Every pitch meeting represented weeks of preparation. Every investor conversation meant explaining not just our technology, but why this specific approach could reach millions of people that current solutions miss. Why simplicity, easier to use technology that the masses can adopt, is as powerful as more advanced algorithms that require a lot more management and work from the user.
The diabetes technology space is crowded, and investors have seen plenty of "revolutionary" solutions that didn't pan out. We had to prove that Luna wasn't just another insulin pump—it was a fundamentally different approach that could expand the entire market for automated insulin delivery.
Jon Brilliant, our co-founder and CFO, lived and breathed these investor presentations. "Every conversation started with the same question," he told me recently. "'How is this different from existing pumps?' By the end, investors understood that we weren't competing with traditional pumps—we were creating an entirely new category."
Not all funding is created equal. We weren't just looking for money; we were seeking partners who understood our vision and could help us execute it. When Vensana Capital emerged as our lead investor, we knew we'd found the right match.
Justin Klein, MD, JD, co-founder and Managing Partner at Vensana Capital, got it immediately. During our first meeting, he said something that stuck with all of us: "Luna is solving a challenge the diabetes field has struggled with for decades—bringing the benefits of automation to injection users."
That wasn't investor speak. That was someone who understood the real problem we're solving.
Throughout the fundraising process, we never lost sight of why this matters. Every delayed timeline meant more nights of poor sleep for people with diabetes. Every regulatory hurdle meant more mornings of waking up exhausted and frustrated.
We regularly hear from the diabetes community about their struggles with nighttime glucose control. Parents of children with Type 1 diabetes who set multiple alarms to check blood sugar levels. Adults with Type 2 diabetes who avoid evening activities because they're worried about overnight complications. Healthcare providers who know their patients need better solutions but have limited options to offer.
These aren't just market opportunities—they're real people whose lives could be dramatically improved by accessible automated insulin delivery. That's the weight we carry, and it's what drove us through every challenging moment of the fundraising process.
This funding allows us to accelerate regulatory submissions, conduct the clinical studies needed to prove Luna's safety and efficacy, and build the manufacturing capacity to reach millions of people.
But perhaps most importantly, it lets us set the foundation for expanded clinical and market access programs. Making Luna accessible means working with insurance companies, healthcare providers, and diabetes educators to ensure that cost and complexity don't become barriers to adoption.
We're also investing heavily in user education and support. Even the simplest technology requires proper training and ongoing support. This funding allows us to build the infrastructure needed to onboard users successfully and support them throughout their journey with Luna.
Closing Series A funding is just the beginning. Now comes the hard work of getting it cleared by the FDA (to start) so that we can reach millions of people. We're accelerating our regulatory timeline, enhancing our product, starting to build manufacturing capacity, and building partnerships that will make Luna widely available.
The diabetes technology landscape is evolving rapidly, and we're positioned to be part of that transformation. But we're not just trying to grab market share—we're trying to expand the entire market by serving people who existing solutions have left behind.
Each milestone brings us closer to our ultimate goal: making automated insulin delivery so simple and accessible that it becomes the standard of care for insulin users worldwide.
Building Luna Health has taught us that the best innovations don't just solve technical problems—they solve human problems. Every algorithm we refine, every hardware component we optimize, and every regulatory document we submit is in service of real people living with diabetes.
The fundraising process reminded us daily why this mission matters. Investors didn't just evaluate our technology or our market opportunity—they evaluated our commitment to the people we serve. That's what separated the investors who joined our round from those who passed.
As we move forward with the support of Vensana Capital and our other investors, we carry the responsibility of delivering on our promises. Not just to our investors, but to the millions of people who could benefit from better nighttime glucose control.
Luna Health exists to solve the single largest problem in diabetes care: nighttime glucose control for pen users. With our Series A funding secured, we're one step closer to making that solution a reality.
The path ahead isn't easy, but it's clear. We'll continue developing technology that puts people first, building partnerships that expand access, and creating solutions that fit into real lives rather than demanding that lives revolve around technology.
Every person who sleeps better with Luna, every parent who worries less, every healthcare provider who has better options to offer—that's the real return on investment we're building toward.
The diabetes community has been waiting too long for accessible automated insulin delivery. With our investors' support and our team's dedication, we're finally ready to deliver it.